Roberta Soscia
YOU?
Author Swipe
View article: Molecular clustering on ctDNA improves the prognostic stratification of patients with DLBCL compared with ctDNA levels
Molecular clustering on ctDNA improves the prognostic stratification of patients with DLBCL compared with ctDNA levels Open
Circulating tumor DNA (ctDNA) levels can help predict outcomes in diffuse large B-cell lymphoma (DLBCL), but its integration with DLBCL molecular clusters remains unexplored. Using the LymphGen tool in 77 DLBCL cases with both ctDNA and ti…
View article: Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma
Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma Open
In diffuse large B-cell lymphoma (DLBCL) treatment response relies on imaging. We investigated the potential value of molecular measurable residual disease (MRD) on circulating tumor DNA (ctDNA) to predict patient outcomes. We retrospectiv…
View article: MRD Monitoring By Euroclonality IGH Based NGS Approach Predicts Outcome in Follicular Lymphoma Patients Lacking a Conventional BCL2::IGH Marker: A Substudy from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial
MRD Monitoring By Euroclonality IGH Based NGS Approach Predicts Outcome in Follicular Lymphoma Patients Lacking a Conventional BCL2::IGH Marker: A Substudy from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial Open
Background. Despite durable clinical responses achieved by chemo-immunotherapy in follicular lymphoma (FL) patients, most of them eventually relapse. Actually, minimal residual disease (MRD) analysis based on the detection of BCL2::IGH rea…
View article: P1232: NON-INVASIVE MINIMAL RESIDUAL DISEASE ANALYSIS BY IMMUNOGLOBULIN GENE REARRANGEMENTS ON CIRCULATING TUMOR DNA PREDICTS THE OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
P1232: NON-INVASIVE MINIMAL RESIDUAL DISEASE ANALYSIS BY IMMUNOGLOBULIN GENE REARRANGEMENTS ON CIRCULATING TUMOR DNA PREDICTS THE OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA Open
Topic: 20. Lymphoma Biology & Translational Research Background: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with genetic diversity and variable outcomes. The standard monitoring of DLBCL response to therapy relies on …
View article: MOLECULAR CLUSTERING ON CTDNA IMPROVES THE PROGNOSTIC STRATIFICATION OF DLBCL PATIENTS COMPARED TO CTDNA LEVELS
MOLECULAR CLUSTERING ON CTDNA IMPROVES THE PROGNOSTIC STRATIFICATION OF DLBCL PATIENTS COMPARED TO CTDNA LEVELS Open
Introduction: The quantification of circulating tumor DNA (ctDNA) on the liquid biopsy at the time of diagnosis allows to stratify the outcome of diffuse large B-cell lymphoma (DLBCL) patients but its integration with molecular clustering …
View article: Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies? Open
Minimal/measurable residual disease (MRD) monitoring is progressively changing the management of hematologic malignancies. The possibility of detecting the persistence/reappearance of disease in patients in apparent clinical remission offe…
View article: Sialylation regulates migration in chronic lymphocytic leukemia
Sialylation regulates migration in chronic lymphocytic leukemia Open
Sialylation is the terminal addition of sialic acid to underlying glycans. It plays a prominent role in cell adhesion and immune regulation. Sialylated structures found on adhesion molecules, such as CD49d, mediate the interactions between…
View article: Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia
Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia Open
Minimal/measurable residual disease (MRD) evaluation has resulted in a fundamental instrument to guide patient management in acute lymphoblastic leukemia (ALL). From a methodological standpoint, MRD is defined as any approach aimed at dete…
View article: Treatment with ibrutinib does not induce a <I>TP53</I> clonal evolution in chronic lymphocytic leukemia
Treatment with ibrutinib does not induce a <i>TP53</i> clonal evolution in chronic lymphocytic leukemia Open
Ibrutinib is active both in treatment-naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients, including those with unmutated immunoglobulin heavy chain variable region (IGHV) genes and TP53 disruption.1-3 The …
View article: Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia
Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia Open
Minimal residual disease (MRD) is the most powerful prognostic factor in pediatric acute lymphoblastic leukemia (ALL). Real-time quantitative polymerase chain reaction (RQ-PCR) represents the gold standard for molecular MRD assessment and …
View article: Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances Open
Introduction: Acute lymphoblastic leukemia (ALL) is the first neoplasm where the assessment of early response to therapy by minimal residual disease (MRD) monitoring has proven to be a fundamental tool to guide therapeutic choices. The mos…